Aevi Genomic Medicine Inc (NASDAQ:GNMX) has earned a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.
Brokers have set a 12-month consensus price target of $5.00 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given Aevi Genomic Medicine an industry rank of 214 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine upgraded shares of Aevi Genomic Medicine from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd.
GNMX traded down $0.03 on Thursday, reaching $1.15. The company had a trading volume of 1,415 shares, compared to its average volume of 147,250. Aevi Genomic Medicine has a 1 year low of $1.01 and a 1 year high of $2.65. The stock has a market cap of $71.21 million, a PE ratio of -1.40 and a beta of 1.12.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). analysts anticipate that Aevi Genomic Medicine will post -0.6 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Renaissance Technologies LLC raised its holdings in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 515.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,600 shares of the biotechnology company’s stock after purchasing an additional 78,400 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of Aevi Genomic Medicine worth $112,000 as of its most recent filing with the SEC. 22.83% of the stock is owned by institutional investors and hedge funds.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.